A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Day Dose Study to Assess the Safety and Tolerability of JNJ-67670187 in Healthy Participants
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs JNJ 67670187 (Primary) ; Antibacterials; Laxatives
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 05 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Feb 2019 Planned number of patients changed from 144 to 102.
- 07 Feb 2019 Planned End Date changed from 25 May 2020 to 16 Dec 2019.